i-lung® is designed to be the world’s first wearable artificial lung,
a new class of devices that will serve as a steppingstone toward
long-term pulmonary support and, ultimately, to an implantable
HEILBRONN, Germany–(BUSINESS WIRE)–XENiOS®,
a commercial-stage medical device company, announced today it expects to
receive CE-marking for its i-lung® device within 18 months.
XENIOS expects to launch i-lung® in 2017. Currently available
devices lack durability and wearability. Additionally, the size of
current systems restricts patient mobility and limits quality of life.
i-lung represents an innovative and first-of-its-kind fully wearable
artificial lung for long-term use in a hospital environment.
“The availability of i-lung will open the door to significant medical
progress for respiratory support. For many patients in lung failure
currently undergoing invasive mechanical ventilation, the use of i-lung
is designed to avoid sedation and immobility, thus creating active,
self-managed patients,” said Georg Matheis, MD, Managing
Director & Founder of XENIOS. “In addition, i-lung is designed to be
used to bridge the waiting time for a donor organ
“Of special note,” added Juergen Boehm, MD, Managing Director of Xenios,
“i-lung paves the way for XENiOS to continue development of a bioartificial
lung for use by patients outside of a hospital environment analogous to
current artificial heart protocols, which will represent a paradigm
shift in the approach to long-term respiratory support.”
i-lung is the result of the successful completion of the AmbuLung
project, a three-year R&D consortium project funded by the European
Union’s FP7 Program that developed the basis for i-lung, the world’s
first-of-its-kind wearable artificial lung. In addition to XENiOS,
the consortium included Fraunhofer IGB (Stuttgart, Germany); Imperial
College of Science, Technology and Medicine (London, UK); and, the University
of Florence (Italy).
“We are forever indebted to the vision and the work of Professor
Dame Julia Polak, who passed away last year,” said Dr. Matheis.
“Julia and I co-founded the i-lung project, and because of her enormous
contribution i-lung is now a reality, and a bioartificial next-gen of
i-lung on the horizon.” The author of some 1,000 original papers, 115
review articles and editor or author of 25 books, Julia Polak, MD, PhD,
was one of the most widely cited researchers in her field, and had
undergone a heart lung transplant. She served on several national and
international tissue engineering and stem cell advisory panels, and was
the European editor of the journal Tissue Engineering.
Funding for the commercialization of i-LUNG® has already been procured.
XENIOS announced in September 2015 that it received an eight-figures
cash infusion from existing investors, in part to fund CE-marking and
launch of i-LUNG, led by ZFHN,
one of the largest Single Family Offices in Germany investing in
XENiOS AG is a privately held medical technology company that is
comprised of two product brands, novalung® and i–cor®,
that run on a single XENiOS® console. The XENIOS platform is
designed to provide at least four essential advantages with its
minimally invasive lung and heart therapies: (1) patients are awake and
mobile;(2) self-actuated patients facilitate improved outcomes; (3)
there is no ventilator-associated lung injury or pneumonia; (4)
additionally, the XENIOS platform maintains a physiologic natural pulse
designed to protect the heart.
Ronald Trahan Associates
Ronald Trahan, APR, +1-508-359-4005, ext.